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Objective: Radiopaque markers are commonly deployed
following breast biopsies to indicate the location of the
targeted lesion. A frequently encountered complication is
the displacement of these markers. This study compared
the degree of displacement among four newer generation
markers after stereotactic core needle biopsy.
Methods: 80 consecutive biopsies were performed at
three breast centre sites. The markers included: HydroMARK® (Mammotome, Cincinnati, OH), MammoMARK™
(Mammotome, Cincinnati, OH), MammoStar™ (Mammotome, Cincinnati, OH) and SecurMark® (Hologic, Bedford,
MA). Each marker was composed of a radiopaque core
with a unique polymeric encasing component. Postprocedure mammograms were obtained and the degree
of marker displacement was measured.
Results: MammoMARK™ exhibited the greatest mean net
displacement, followed by HydroMARK®, SecurMark® and
MammoStar™ (13.9, 7.7, 5.8 and 4.7 mm, respectively),
although these differences did not reach statistical

significance (p 5 0.398). 73% of the markers did not
displace at all. However, in the 19 of 22 markers in which
displacement occurred, the distance from the biopsy
cavity was .10 mm. No statistically significant contributing factors to predict displacement were found.
Conclusion: Newer generation biopsy markers perform
comparably with one another. However, clinically
significant and unpredictable marker displacement
persists. Compared with multiple similar studies of
older generation bare metallic markers, the overall
displacement rate of newer generation markers seems
to be lower, possibly owing to the use of polymeric
embedding agents that self-expand within the
biopsy cavity.
Advances in knowledge: This article compares the postprocedure displacement of breast biopsy markers, which
have not been evaluated or discussed in detail since
markers with polymeric embedding agents gained widespread use.

INTRODUCTION
Stereotactic vacuum-assisted biopsy (SVAB) has become
the standard of care for the work-up of suspicious breast
calciﬁcations and other sonographically occult lesions. The
procedure is minimally invasive, more convenient and
signiﬁcantly less expensive than surgical excisional biopsy.
However, when there is a histologic diagnosis of malignancy, it is often necessary to proceed to lumpectomy.
Frequently, all radiographic evidence of the lesion can be
completely removed after SVAB, reportedly in up to
50–72% of cases.1 This can make pre-operative localization
challenging, forcing the radiologist to have to rely on
mammographic landmarks and/or the presence of a haematoma for targeting. In the early to mid-1990s, the
placement of a radiopaque metallic post-biopsy clip began
gaining popularity in cases where the mammographic

abnormality was determined to be no longer visible.2 Since
then, the use of post-procedure markers after SVAB has
become widespread, with most institutions, including ours,
routinely placing the markers after all breast biopsies.
Studies have shown that clear margins are obtained in
90–92% of excisional specimens when lesions are localized
using biopsy markers vs 31–62% when wire localization is
used alone.2,3
A well-known complication of marker use is the immediate
displacement from the biopsied lesion. Most cases of displacement are believed to be caused by the so-called “accordion effect”.2,4–9 During the SVAB procedure and
subsequent marker placement, the breast is in compression. After the procedure, when released from compression, the breast resumes its normal shape and the marker
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can displace along the axis of compression (the z-axis). Causes
for delayed marker migration, which occurs any time in the
non-immediate interval following biopsy, include displacement
by a haematoma, simple migration within the fatty tissue and
changes secondary to neoadjuvant chemotherapy.10,11 Any instance in which a marker is distant from the targeted lesion
poses a risk that a malignancy may be incompletely excised at
surgery, particularly when displacement of the marker from the
biopsy cavity goes unrecognized.
The ﬁrst generation of breast biopsy markers were bare metallic
clips, usually composed of either titanium or stainless steel.
Many of these markers were designed to physically attach to the
biopsy cavity wall, similar to vascular ligating clips. Others were
simply deposited within or near the biopsy cavity.2,4 Use of bare
metallic biopsy markers continues today at many institutions.
Performance of these markers is variable, with reported rates of
displacement ,10 mm ranging from 54 to 99% in the
literature.1,4–6,12–14 However, some of these higher published
numbers are thought to be inﬂated, as displacement was measured with the breast still under compression on the stereotactic
table, before the accordion effect is thought to take place.6,12,14
In 2003, the ﬁrst marker embedded within a biocompatible
polymeric material was introduced to the market, the MammoMARK™ (Mammotome, Cincinnati, OH). In a comparative
analysis, Rosen et al4 showed that the MammoMARK™ resulted
in a statistically signiﬁcant decrease in the number of occurrences of marker-to-biopsy site displacement .10 mm vs older
generation bare metallic markers (16 vs 44%, respectively).
However, this study was somewhat limited by the relatively low
number of markers with embedding agents (n 5 31) and bare
metallic markers (n 5 43). Moreover, markers were not deployed
following all biopsy cases—only cases in which the radiologist
determined that the lesion was no longer mammographically
visible, and the patients were not randomized, potentially introducing a selection bias. The embedding agent used in the
MammoMARK™ is collagen. Markers employing various other
kinds of polymeric embedding materials have since come to
market and are now widely used. These embedding materials
attempt to limit post-biopsy displacement by a common
mechanism: expansion within the biopsy cavity immediately
after deployment.
While several authors have studied the displacement of breast
biopsy clips, after performing a systematic literature review, we
found no published journal articles comparing newer generation
markers with polymeric embedding agents with each other. We
prospectively evaluated the performance of four newer generation breast biopsy site markers immediately following SVAB
using post-procedure mammograms.
METHODS AND MATERIALS
Upon obtaining approval from our institutional review board,
four commercially available biopsy site markers composed of
a central metallic or ceramic radiopaque core encased in unique
polymeric coatings were evaluated to determine the degree of
displacement following SVAB. The institutional review board
waived the requirement to obtain informed consent from the
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patients because the study protocol did not differ from the
standard of care in the routine work-up of suspicious breast
lesions at our institution. The markers included the MammoMARK™, HydroMARK® (Mammotome, Cincinnati, OH),
MammoStar™ (Mammotome, Cincinnati, OH) and
SecurMark® (Hologic, Bedford, MA) (Table 1, Figure 1). The
markers were selected based on those we currently held in stock.
Bare metallic clips were not evaluated because they are no longer
considered the standard of care at our institution and are not
stocked.
Between 15 May 2014 and 19 February 2015, 74 consecutive
patients underwent SVAB for a suspicious mammographic abnormality by a single fellowship-trained breast radiologist at one
of three breast centre campuses. One of the campuses was located in an urban setting in Detroit, Michigan, USA proper, and
the other two in suburban settings in the greater Detroit Metropolitan Area. Inclusion criteria were any female with a breast
imaging reporting and data system® category 4 or 5 assessment
with recommendation for SVAB. Patients were excluded if SVAB
was contraindicated for any reason, including the inability to
remain in the position required for the duration of the procedure, weight greater than the weight limit of the biopsy table
(300 lbs), inability to visualize the breast lesion mammographically or inaccessible position of the lesion within the
breast. All SVABs were performed in the prone position using
the Hologic Eviva® nine-gauge system and Hologic MultiCare
Platinum® stereotactic biopsy table (Bedford, MA). 6–12 samples were taken per lesion depending on the performing radiologist level of conﬁdence that the lesion was adequately
sampled.
Patients were randomly assigned to receive one of the four biopsy markers using a randomization schedule created by SAS v.
9.4 (SAS Institute Inc., Cary, NC). Five of the patients underwent biopsies of two lesions on the same day immediately
following one another, and different biopsy markers were used
in these instances. One patient underwent two biopsies on the
same breast separated by a time interval of 1 week. A total of 80
biopsy markers were deployed, with 20 markers from each
marker group. The markers were placed according to the inservice training provided by each marker vendor representative.
Per recommended guidelines, all markers were deployed
through the end of the introducer cannula after vacuum assistance was turned off. Following each biopsy case, the breast was
slowly decompressed and manual pressure was applied for several minutes to obtain haemostasis.
All patients received post-biopsy 90° true lateral and craniocaudal mammograms immediately following the procedure
(within 15 min) per our institution standard operating procedures to verify and measure marker location in relationship to
the targeted biopsy cavity. These images were compared with
true lateral and craniocaudal images that were obtained during
the previous diagnostic mammography work-up. The markerto-biopsy site distance was determined using the direct measurement method in which a line was drawn from the edge of
the biopsy cavity to the proximal edge of the marker on both
craniocaudal and true lateral views (Figure 2). Prior to
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Table 1. List of breast biopsy site markers included in study and material properties

Brand

Manufacturer

Radiopaque marker material

Embedding material

MammoMARK™

Mammotome, Cincinnati, OH

Titanium

Collagen

HydroMARK®

Mammotome, Cincinnati, OH

Stainless steel or titanium

Polyethylene glycol-based hydrogel

MammoStar™

Mammotome, Cincinnati, OH

Ceramic

Lyophilized (freeze-dried) beta-glucan gel

SecurMark®

Hologic, Bedford, MA

Stainless steel or titanium

Bioabsorbable suture-like netting (glycoprene)

measuring, the biopsy cavity was conﬁrmed to be located within
the targeted lesion. If the lesion was no longer mammographically visible, soft-tissue landmarks were used to conﬁrm
that the appropriate lesion was biopsied. The distance was
measured by the same radiologist who performed the procedure.
In addition, patient age and lesion characteristics including the
mammographic description of the lesion, size of lesion, assigned

breast imaging reporting and data system® category and ﬁnal
pathology were recorded (Table 2). Variables related to biopsy
technique including breast tissue composition, thickness of the
breast under compression on the stereotactic table, biopsy approach, number of core samples obtained, whether a second
biopsy was performed on the same day and the presence of
a post-procedure haematoma were also documented (Table 3).

Figure 1. Photographs of the four markers evaluated in the
study. The MammoMARK™ (Mammotome, Cincinnati, OH),
HydroMARKâ (Mammotome, Cincinnati, OH) and MammoStar™ (Mammotome, Cincinnati, OH) are depicted in both their
hydrated and non-hydrated states, courtesy of Mammotome.
The SecurMarkâ (Hologic, Bedford, MA) was provided courtesy of Hologic.

Measurements of displacement were broken down into x–y-axis
(orthogonal to compression), z-axis (plane of compression) and
net displacement, which were calculated using the Pythagorean
theorem. The markers were compared using the Kruskal–Wallis
test to evaluate for statistically signiﬁcant differences in biopsy
cavity-to-marker distances. Spearman’s rank tests were used to
analyze whether any of the aforementioned variables listed above
had a correlation with net displacement of the markers as
a group. Analysis was performed using SAS v. 9.4. Statistical
signiﬁcance was deﬁned as a p-value ,0.05.
RESULTS
22 (28%) of the 80 markers were displaced from the biopsy site
on post-procedure mammograms. The median marker-tobiopsy site displacement for all four groups was 0 mm. MammoMARK™ exhibited the greatest mean net displacement
(13.9 mm), followed in order by HydroMARK®, SecurMark®
and MammoStar™ (Table 4). However, the differences in displacement among the four tested markers did not reach statistical signiﬁcance (p 5 0.398). Of the four markers,
MammoMARK™ had the greatest maximal net displacement (73.4 mm).
The most cases of marker displacement occurred with MammoMARK™ [8/20 (40%)], with the majority displacing
.10 mm [7/20 (35%)]. MammoStar™ and SecurMark® both
had the least number of marker displacement [4/20 (20%)
each]; but again, most of the instances of displacement of these
markers were .10 mm (Table 5). In fact, 19 of the 22 markers
that demonstrated positive displacement were found to be at
a distance .10 mm from the biopsy cavity, indicating that when
there was displacement, it was substantial. This is reﬂected by
a mean distance of 29.2 mm from the biopsy cavity among the
22 markers in which displacement occurred. When displacement
occurred in just 1 axis (17 of the 22 cases), it was exclusively in
the z-axis.
We found no statistically signiﬁcant correlation between patient
and lesion characteristics and the incidence of displacement when
data from all four types of markers were aggregated (Table 2).
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Figure 2. 63-year-old female with new grouped amorphous calcifications (arrows) at 4 o’clock within the left breast anteriorly for
which stereotactic vacuum-assisted biopsy was recommended. (a, b) The calcifications were biopsied and a MammoMARK™
(Mammotome, Cincinnati, OH) was deployed. Immediate post-procedure mammogram images reveal 40 mm of medial
displacement from the biopsy cavity (c, d). LCC, left craniocaudal view; LML, left mediolateral view.

80% of the biopsied lesions involved calciﬁcations and 22 biopsies yielded malignant results. Including diagnoses with highrisk pathology, 24 cases proceeded to surgery at our institution.
Of the eight high-risk lesions, one was upgraded to malignancy
at surgical excision. Positive-predictive value was 29.1%. We also
found that factors related to biopsy technique were not associated with displacement (Table 3). It should be noted that some
lesion characteristics and variables related to technique had low
n-values, which limits their interpretability. For instance, just
two females in the study had extremely dense breast tissue
composition. Medial approach was also uncommonly utilized
(n 5 7). However, when a biopsy was performed using a medial
approach, it is interesting to note that four out of seven cases
exhibited displacement in both the x–y and z-axes. Only one
other instance of x–y displacement occurred during the study (in
which lateral approach was used) and this marker also displaced
along the z-axis. Although the “approach” category did not
technically achieve statistical signiﬁcance (p 5 0.067), it appears
there is a trend towards correlation. Four cases (involving
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MammoMARK™, HydroMARK® and two MammoStar™
markers) were complicated by haematomas measuring 9.0, 2.7,
7.3 and 1.5 cm, respectively. In all of these cases, no displacement from the biopsy cavity was observed.
DISCUSSION
In general, no single marker performed signiﬁcantly better or
worse than the others evaluated in this study, with most [58/80
(73%)] markers showing no displacement on two-view mammography immediately following SVAB. This implies that the
presence of a biocompatible polymeric embedding agent is more
important than the speciﬁc type of polymer used when it comes
to minimizing the occurrence of post-biopsy displacement. Our
results reveal that 19/80 (24%) of the markers displaced
.10 mm, which roughly approximates Rosen et al’s study of the
MammoMARK™ marker in which 5/31 (16%) markers were
located .10 mm from the target. Additional studies on the
immediate post-procedure displacement of newer generation
breast biopsy markers with embedding agents were not found

Br J Radiol;89:20160149

Full paper: Comparative study to evaluate displacement of breast biopsy markers

BJR

Table 2. Summary of descriptive data related to patient demographics and lesion characteristics

Factor
Age (years)

Variable

Result

Mean (SD)

57.9 (12.4)

Calciﬁcations

60 (75.0%)

Focal asymmetry

5 (6.3%)

Mass

11 (13.8%)

Calciﬁcations with focal asymmetry or mass

4 (5.0%)

Mammographic description

Size of lesion (mm)

p-value
0.122

0.436

Mean (SD)

16.6 (18.6)

3

2 (2.5%)

4A

27 (33.8%)

4B

38 (47.5%)

4C

10 (12.5%)

BI-RADS® category

0.585

0.822
5

1 (1.3%)
a

None

2 (2.5%)

Benign

49 (61.3%)

Malignant

22 (27.5%)

High risk

8 (10.0%)

Discordant results without follow-up

1 (1.3%)

Pathology

0.726

BI-RADS, breast imaging reporting and data system; SD, standard deviation.
Numbers in the result column represent the n-value, unless otherwise indicated. Correlation between variables and displacement was analyzed
(statistical significance was set at p , 0.05).
a
Two cases were referrals from outside hospitals in which reports were not available prior to biopsy.

after performing a literature review. There are more robust data
available regarding the displacement of the older generation bare
metallic markers. In similar study protocols to our own, Rosen
et al,4 Chaveron et al5 and Kass et al1 found immediate postSVAB displacement rates of bare metallic markers measuring
.10 mm of 44, 32 and 46%, respectively. However, of these
three studies, Rosen et al were the only group of investigators to
utilize a prospective technique like we did in our study.
Three of the four markers investigated in this study (MammoMARK™, HydroMARK® and MammoStar™) have embedding
agents that expand via osmotic water absorption and the fourth,
the SecurMark®, utilizes a self-expanding net. The mechanism
by which embedding agents minimize displacement is thought
to relate to the fact that these types of markers are deployed
directly into the biopsy cavity, exerting force on the walls as they
expand and anchoring them within the cavity.4 Self-expansion
continues over the ensuing minutes and hours, which secures
them within the cavity further and helps to decrease the incidence of long-term migration. Delayed migration can occur
from days to over 1 year after the initial biopsy and is a clinically
relevant issue itself.15 However, it should be noted that our
results do not apply to long-term migration, which was not
evaluated in this study in order to avoid additional radiation
exposure to the patients.
Besides reducing the incidence of displacement, polymeric embedding agents offer additional beneﬁts compared with bare
metallic markers. They are highly visible sonographically,
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especially when hydrogel is used (e.g. HydroMARK®), as we have
analyzed in prior research.16 This can be useful for ultrasoundguided pre-operative localization procedures and even for
intraoperative ultrasound-guided excisional biopsies and lumpectomies. Furthermore, the pressure of the polymeric embedding agent against the biopsy cavity wall reduces the chance of
post-procedure haematoma formation. Collagen (used in the
MammoMARK™) has the added beneﬁt of activating the coagulation cascade, which confers enhanced haemostasis.2,4,17
One area of concern was that when the markers did displace in
our study, the distance from the biopsy cavity was considerable
—10 mm or more in 86% of the displaced cases. This is
speculated to relate, at least in part, to the slippery surface of the
gel-like polymeric component of some of the markers. Consequently, if the marker is not deployed exactly within the biopsy
cavity, the self-expanding nature of the markers could result in
extrusion along the biopsy tract. In fact, in a retrospective review
by Klein et al,18 breast surgeons who were attempting to perform
excisional biopsies using intraoperative ultrasound alone
(without a separate pre-operative localization procedure)
reported extrusion of the HydroMARK® in 14 of 31 cases when
the biopsy tract was traversed during surgery.
Our results are in agreement with previous literature, suggesting
that the accordion effect is the primary means of immediate
post-biopsy displacement, given that all markers displacing in
one dimension did so along the z-axis. Uematsu et al8 examined
variables that could predict when markers will be more likely to

Br J Radiol;89:20160149
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Table 3. Summary of variables related to stereotactic biopsy technique

Factor

Variable

p-value

Result

Fatty

9 (11.3%)

Scattered

42 (52.5%)

Heterogeneous

27 (33.8%)

Extremely

2 (2.5%)

#40

12 (15.0%)

.40

68 (85.0%)

Superior

27 (33.8%)

Inferior

19 (23.8%)

Lateral

27 (33.8%)

Tissue composition

0.657

Thickness in compression on biopsy table (mm)

0.858

Approach

0.067
Medial

Number of core samples

7 (8.8%)

Mean (SD)

Single vs second same-day biopsy performed (n 5 75)

6.6 (1.8)

Single

70 (93.3%)

Double

5 (6.7%)

No

76 (95.0%)

Yes

4 (5.0%)

0.119
0.311

Haematoma

0.340

SD, standard deviation.
Numbers in the result column represent the n-value, unless otherwise indicated. Correlation between variables and displacement was analyzed
(statistical significance was set at p , 0.05).

displace via the accordion effect and found that breast thickness
was the only statistically signiﬁcant predictor, with thinner
compressed breasts tending to exhibit greater degrees of displacement. Other variables, including age of the patient, breast
tissue composition and number of specimens were not useful in
predicting marker displacement. We also evaluated multiple
variables to see whether marker displacement could be predicted
in our study group. We did not ﬁnd a statistically signiﬁcant
correlation with any of these variables, including breast thickness. The average breast thickness in our study population was
53 mm, while in Uematsu et al’s study, it was 37 mm. Perhaps
this may have contributed to our discrepant results.
Aside from using markers with polymeric embedding agents,
other strategies for reducing displacement include gently releasing the breast from compression and closely following
manufacturer instructions when deploying the markers. A study
by Chaveron et al5 also suggested that when feasible, using

mediolateral rather than craniocaudal compression tended to
decrease the incidence of displacement, although the reasoning
behind this was uncertain. They postulate that breast ptosis or
gravity effects may have played a role. We did not see this same
effect in our study. In fact, more cases of displacement occurred
under craniocaudal compression [13/22 (59%)] in comparison
with mediolateral compression [9/22 (41%)]. Notably, medial
approach seemed to predispose the markers to biaxial displacement in our study. We have no clear explanation as to why
this occurred, but this apparent trend could be investigated in
future research.
With only 4 (5%) cases of post-procedure haematomas, it is not
possible to infer whether this complication inﬂuenced displacement of the newer generation markers, despite there being
no associated marker displacement in these cases. The use of
smaller 11-gauge SVAB devices may decrease post-procedure
bleeding and haematoma formation, although evidence suggests

Table 4. Marker-to-biopsy site displacement of the four markers

Biopsy site marker

n

Net marker-to-biopsy site displacement (mm)
Median

Mean

SD

Range

MammoStar™ (Mammotome, Cincinnati, OH)

20

0

4.7

11.5

0–42.0

SecurMark® (Hologic, Bedford, MA)

20

0

5.8

15.0

0–62.0

HydroMARK® (Mammotome, Cincinnati, OH)

20

0

7.7

15.9

0–56.0

MammoMARK™ (Mammotome, Cincinnati, OH)

20

0

13.9

23.6

0–73.4

SD, standard deviation.
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Table 5. Absolute number and percentage of cases of marker displacement by marker group

Markers
displaced
(net) (%)

Cases of post-procedure displacement
Biopsy site marker

n
z-axis
only

x–y-axis
only

z-axis
and x–y-axis

Total

.0 cm

$1 cm

MammoStar™ (Mammotome,
Cincinnati, OH)

20

4

0

0

4

20

15

SecurMark® (Hologic, Bedford, MA)

20

3

0

1

4

20

20

HydroMARK® (Mammotome,
Cincinnati, OH)

20

4

0

2

6

30

25

MammoMARK™ (Mammotome,
Cincinnati, OH)

20

6

0

2

8

40

35

Total

80

17

0

5

22

27.5

23.8

that this effect is device dependent. Schaefer et al19 showed that the
11-gauge Mammotome® system had a signiﬁcantly lower haematoma rate than the 8-gauge Mammotome®. At our institution, the
Hologic Eviva nine-gauge SVAB system is used for all breast biopsies and is preferred over smaller gauge devices in an attempt to
limit sampling error. In addition, the decrease in the number of
required core samples has itself been correlated with lower incidences of haematoma formation and thus can counterbalance the
risks of taking larger cores.20 Our haematoma rate is lower than
comparable studies, which reached as high as 45%, and may relate
at least in part to our study protocol’s short interval from biopsy to
post-procedure mammogram.21 The haemostatic effect of the
polymeric embedding agents may have also played a role.
Our study was underpowered owing to ﬁnancial constraints and
limited access to the various biopsy markers, which made it
difﬁcult to detect small differences in displacement. However,
repeating this study with a higher n-value may be of limited
clinical yield, given that all biopsy markers had a median displacement of 0 mm and as a group, marker displacement was
unpredictable. Since the study was performed at three clinical
sites, different technologists and nurses participated in the biopsy and post-procedure care, which could have potentially
introduced a confounding variable if different techniques were

used. For example, the duration of post-biopsy manual compression may have varied among sites. Five of the patients in our
study underwent two separate biopsies immediately following
one another. The effects of placing the breast back into compression to perform the second biopsy and the delayed postprocedure mammogram with respect to the ﬁrst biopsy may
have inﬂuenced displacement.
In conclusion, newer generation markers with biocompatible
polymeric embedding agents perform relatively similarly to one
another on immediate post-SVAB mammograms with no statistically signiﬁcant difference in mean displacement among the
four markers that were tested. Furthermore, there was no deﬁnitive evidence to suggest an ability to predict when this displacement may occur. The percentage of markers displacing
.10 mm was in line with the only other known research study
measuring displacement of newer generation breast biopsy
markers, and both are seemingly lower than the reported rate of
displacement of bare metallic markers according to studies utilizing comparable methodological protocols. More research is
necessary to discover methods to further reduce the incidence of
displacement, possibly through markers that self-expand at
a faster rate or are made of a substance that better adheres to the
biopsy cavity wall once deployed.
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